Paltusotine
- Generic Name
- Paltusotine
- Drug Type
- Small Molecule
- Chemical Formula
- C27H22F2N4O
- CAS Number
- 2172870-89-0
- Unique Ingredient Identifier
- F2IBD1GMD3
- Background
Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)).
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
- Conditions
- Carcinoid SyndromeCarcinoid Tumor of IleumCarcinoid Intestine TumorCarcinoid Tumor of LiverCarcinoid TumorCarcinoid Tumor of CecumCarcinoid Syndrome DiarrheaCarcinoid Tumor of PancreasCarcinoid
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05361668
- Locations
- 🇵🇪
Crinetics Study Site Peru #2, Lima, Peru
🇵🇱Crinetics Study Site, Wrocław, Poland
🇵🇪Crinetics Study Site Peru #1, Lima, Peru
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT05192382
- Locations
- 🇬🇧
Crinetics Study Site, London, United Kingdom
🇬🇷Crinetics Study Site (a), Athens, Greece
🇬🇷Crinetics Study Site (b), Athens, Greece
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT04837040
- Locations
- 🇬🇧
Crinetics Study Site, London, United Kingdom
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT04261712
- Locations
- 🇬🇷
Crinetics Study Site 1, Athens, Greece
🇬🇷Crinetics Study Site 2, Athens, Greece
🇬🇧Crinetics Study Site, Leeds, United Kingdom
Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04246749
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT03792555
- Locations
- 🇬🇷
General Hospital of Athens "Gennimatas", Athens, Greece
ðŸ‡ðŸ‡ºSemmelweis University Faculty of Medicine, Budapest, Hungary
ðŸ‡ðŸ‡ºUniversity of Pécs Medical School, Pécs, Hungary
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03789656
- Locations
- 🇺🇸
UCLA Gonda Diabetes Center, Los Angeles, California, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Crinetics Pharmaceuticals Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT03276858
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.